MedTrace Logo

The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

NCT04492735 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2020-07-30

No results posted yet for this study

Summary

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to:

1. Diagnostic accuracy using pathologic correlation as gold standard measure
2. Short and long term event free and overall survival

Conditions

Sponsors & Collaborators

  • Roshni Dasgupta

    lead OTHER

Eligibility

Min Age
1 Day
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-05
Primary Completion
2023-12-31
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492735 on ClinicalTrials.gov